---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-036792"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T04:45:51.463066+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo raises ~$25M in underwritten offering of common stock and warrants; amends prior warrants

## Summary
- Offering of 35.19M shares + pre-funded warrants for 17.79M shares, each with a purchase warrant for 52.98M shares.
- Combined price per share+ warrant is $0.4719; pre-funded warrant+ warrant at $0.4619; gross proceeds ~$25M.
- Existing warrants held by investor repriced from $1.00 to $0.4719 and expiration extended to 5.5 years from closing.
- Closing expected February 4, 2026; proceeds for general corporate purposes.

## SEC filing metadata
- accession: 0001193125-26-036792
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/0001193125-26-036792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/d101629d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-036792
- JSON: https://secwatch.observer/filing/0001193125-26-036792.json
- Plain text: https://secwatch.observer/filing/0001193125-26-036792.txt

## Key facts
- Material Agreements
  SANGAMO THERAPEUTICS, INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC valued at approximately $25.0 million (effective 2026-02-03).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC
  - Value: approximately $25.0 million
  - Effective: 2026-02-03
  source text: On February 3, 2026, Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. and Wells Fargo Securities, LLC
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001233/000119312526036792/0001193125-26-036792-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.